FreeTheAI

FDA Accepts Atara Biotherapeutics Tab-cel Application with Decision Target Date Set for March 2027

BullishHigh impact
ATRA$9.31 −0.80%

The U.S. Food and Drug Administration has accepted the resubmitted Biologics License Application for tabelecleucel (Tab-cel) from Atara Biotherapeutics, Inc. (ATRA). The treatment is proposed as a standalone therapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The regulatory agency assigned the filing a Class 2 review with a Prescription Drug User Fee Act target action date of March 31, 2027.

The acceptance re-establishes a clear U.S. regulatory path for the drug following earlier setbacks. If approved by the FDA, Atara will receive a $31.0 million milestone payment under its commercial agreement with partner Pierre Fabre. Atara is also eligible to receive double-digit tiered royalties on potential U.S. sales, providing liquidity and an ongoing revenue stream upon commercialization.

Investors will monitor progress toward the March 31, 2027 decision deadline. Partner Pierre Fabre holds the application and manages ongoing agency interactions, making execution outside of Atara's direct control. Tab-cel retains both Breakthrough Therapy and Orphan Drug designations from the agency.

Key points

  • FDA accepts the resubmitted BLA for tabelecleucel (Tab-cel) to treat EBV-positive PTLD.
  • The agency granted a Class 2 review with a PDUFA target decision date of March 31, 2027.
  • Regulatory approval would trigger a $31.0 million milestone payment from partner Pierre Fabre.
  • Atara is eligible for double-digit tiered royalties on commercial sales if Tab-cel is approved.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What did the FDA decide regarding Atara Biotherapeutics' Tab-cel?

The FDA accepted Atara Biotherapeutics' resubmitted Biologics License Application for Tab-cel as a treatment for EBV-positive PTLD and assigned it a Class 2 review.

When is the PDUFA target action date for Tab-cel?

The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of March 31, 2027.

What financial milestones does Atara gain if Tab-cel is approved?

Approval of Tab-cel would trigger a $31.0 million milestone payment from commercial partner Pierre Fabre, alongside double-digit tiered royalties on U.S. sales.